Jpmorgan Chase & CO Cognition Therapeutics Inc Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 70 shares of CGTX stock, worth $133. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70
Previous 35
100.0%
Holding current value
$133
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CGTX
# of Institutions
51Shares Held
9.4MCall Options Held
0Put Options Held
0-
Pathstone Family Office, LLC Englewood, NJ2.21MShares$4.21 Million0.02% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.9MShares$3.62 Million1.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA922KShares$1.76 Million0.0% of portfolio
-
Awm Investment Company, Inc. New York, NY650KShares$1.24 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL500KShares$955,0000.01% of portfolio
About COGNITION THERAPEUTICS INC
- Ticker CGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,710,700
- Market Cap $43.4M
- Description
- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...